Release Date: March 23, 2022
Expiration Date: March 22, 2023

Target Audience
This activity is intended for community and academic medical oncologists, hematologists, hematologic oncologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with CLL.

Educational Objectives
Upon completion of this activity learners should be able to:

• Identify various disease and patient-related factors that impact the selection of BTK inhibitor use in patients with CLL
• Evaluate clinical trial data of BTK inhibitors that are currently approved for the treatment of patients with CLL
• Assess trial results of investigational BTK-based approaches to the treatment of CLL, including monotherapy and combination approaches
• Review strategies for improving patient outcomes, including optimal selection and sequencing of therapy, adverse event management, as well as oral adherence strategies

Continuing Education

In support of improving patient care, this activity has been planned and implemented by University of Nebraska Medical Center and Bio Ascend.  University of Nebraska Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The University of Nebraska Medical Center designates this enduring material for a maximum of .75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Agenda

• Welcome & Introductions
• Rationale for Targeting Bruton Tyrosine Kinase (BTK) in Patients With CLL​
• Currently Available BTK Inhibitor-Based Strategies: Phase 3 Studies ​
• Future Directions and Emerging Data of BTK Inhibitor Therapy ​
• Considerations for Improving Patient Outcomes ​
• Conclusions

Method of Participation
There are no fees for participating in and receiving CME credit for this activity. During the accredited period, participants must:
1) read the educational objectives and faculty disclosures; 2) study the educational activity; 3) complete the pre- and post-test and evaluation.

Participants who complete the educational activity, pre- and post-test, and evaluation will receive a certificate of credit.

Faculty and Planning Committee Disclosures
As a jointly accredited provider, the University of Nebraska Medical Center (UNMC) ensures accuracy, balance, objectivity, independence, and scientific rigor in its educational activities and is committed to protecting learners from promotion, marketing, and commercial bias. All faculty, planner and others in a position to control continuing education content participating in an accredited continuing education activity are required to disclose all financial relationships with ineligible companies. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. The accredited provider is responsible for mitigating all relevant financial relationships in accredited continuing education. Disclosure of these commitments and/or relationships is included in these activity materials so that participants may formulate their own judgments in interpreting its content and evaluating its recommendations.

This activity may include presentations in which faculty may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications. All materials are included with the permission of the faculty. The opinions expressed are those of the faculty and are not to be construed as those of UNMC.

The accredited provider has mitigated and is disclosing identified relevant financial relationships for the following faculty, planners, and others in control of content prior to assuming their roles.

All faculty and planning committee members have no conflicts to disclose with the exception of the following:

Matthew S. Davids, MD, MMSc​ - Moderator
Associate Professor of Medicine
​Harvard Medical School​
Director of Clinical Research, Division of Lymphoma​
Dana-Farber Cancer Institute​
Boston, Massachusetts

Disclosures
Contracted Research & Publishing: AbbVie Inc., Ascentage Pharma, AstraZeneca, Genentech, MEI Pharma Inc., Pharmacyclics LLC, Surface Oncology, TG Therapeutics, Verastem, Inc.

Consulting Fees: AbbVie Inc., Adaptive Biotechnologies, Ascentage Pharma, AstraZeneca, BeiGene, Celgene Corporation, Genentech, Janssen, MEI Pharma Inc., Pharmacyclics LLC, Research To Practice, TG Therapeutics, Verastem, Inc.

Planning Commitee
The following planning committee members have nothing to disclose:
UNMC: Brenda Ram, CMP, CHCP
Bio Ascend: Patti Bunyasaranand, MS; Dru Dace, PhD; Kraig Steubing

Support
Funding provided by independent educational grants from BeiGene, Ltd.​ and​ Pharmacyclics, an AbbVie Company and Janssen Biotech, Inc.

Technical Requirements
This activity is best experienced using the most current browser (or one back) of Firefox, Chrome, Safari, Internet Explorer, or Microsoft Edge. For all activities featuring audio you must have a sound card and speakers. To view graphic images and references that appear in separate "pop-up" windows, you must have JavaScript and session cookies enabled on your computer. Adobe Acrobat Reader may be required for certain activities.

Select the Continue button below to begin. You may return later if you are unable to complete the activity at this time.